Resultados de la búsqueda 171-180 of 17838 for B cell lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas ... B-cell lymphomas who have failed 1-2 ...
... B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous ...
AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL. Rochester, Minn. This is a Phase 2 global, multi-center, open-label study ...
... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...
... B-cell lymphoma 2 (BCL2) inhibitor. A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma. Jacksonville, Fla ...
... B-cell lymphoma 2 (BCL2) inhibitor. A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma. Rochester, Minn ...
... B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. ... lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. ... lymphoma (B ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?